Prosecution Insights
Last updated: November 04, 2026

Biosckin Molecular & Cell Therapies S A

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Biosckin Molecular & Cell Therapies S A currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This activity is limited to 1 distinct examiner and 1 distinct art unit, showing a concentrated prosecution profile. The 1 pending office action represents the entirety of the company's current interaction with the patent office in this sector. The focus within 1 distinct art unit indicates that the molecular or cell therapy technology is being evaluated within a specific specialized group.

PURDY, KYLE A is the busiest examiner, with 1 busiest examiner pending action. Since 1 distinct examiner, PURDY, KYLE A, is handling the case, the applicant's strategy should be tailored to his specific history and preferences. Practitioners should research the examiner's typical approach to biotechnology claims to better navigate the 1 pending office action. The involvement of 1 distinct examiner and 1 distinct art unit minimizes the complexity of the prosecution.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PURDY, KYLE A 1 40.9% +35.7%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17911435 METHOD FOR PRODUCING HYDROXYAPATITE-BIOGLASS MATERIALS, SAID MATERIALS AND PRODUCTS THEREOF PURDY, KYLE A —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17911435 METHOD FOR PRODUCING HYDROXYAPATITE-BIOGLASS MATERIALS, SAID MATERIALS AND PRODUCTS THEREOF PURDY, KYLE A —

Top Art Units

Art UnitApps
1611 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17911435 METHOD FOR PRODUCING HYDROXYAPATITE-BIOGLASS MATERIALS, SAID MATERIALS AND PRODUCTS THEREOF PURDY, KYLE A 1611 §103§112 Non-Final OA — Pending Sep 14, 2022

Managing Biosckin Molecular & Cell Therapies S A's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Biosckin Molecular & Cell Therapies S A have?

Biosckin Molecular & Cell Therapies S A has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Biosckin Molecular & Cell Therapies S A applications?

Kyle A Purdy has the most, with 1 of Biosckin Molecular & Cell Therapies S A's pending office actions.

What technology area are Biosckin Molecular & Cell Therapies S A's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month